Conclusion:
TIF considered patient with hemoglobinopathies in the vulnerable categories for COVID-19 complication and emphasized that those patients need extra precaution during their recurrent visits to the health care facilities. Mainly due to the lack of current evidence. However, published literature showed a favorable outcome on the majority of thalassemia patients who had COVID-19 infection. However, no data was found regarding the recurrence of this infection. We suggest that all physician should screen those patients for COVID-19 whenever the visited the hospital as they might develop asymptomatic recurrence and even though the clinical course seems to be smooth, screening is essential to control this pandemic and protect this vulnerable population as their outcome still unpredictable, thus offering them close monitoring and controlling their comorbidities.